

Press Release
09 • 15 • 1999

MYRIAD GENETICS FORMS STRATEGIC ALLIANCE WITH GALILEO GENOMICS

Myriad to Acquire 15% Ownership of Galileo

September 15, 1999 - Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has formed a strategic collaboration with Galileo Genomics, a privately held Canadian biotechnology company. The collaboration provides Myriad with access to DNA samples from patients in the French-Canadian population of Quebec. As part of the collaboration, Myriad will acquire a 15% ownership in Galileo Genomics through a \$750,000 equity investment.

Along with Myriad's equity investment in Galileo Genomics, Myriad will fund research at Galileo. The 18-month collaboration will initially focus on the collection and analysis of DNA samples from patients with heart disease, obesity and depression. Myriad has also reserved a right of first refusal on DNA samples associated with other important diseases of potential interest to the Company. Myriad will receive exclusive worldwide diagnostic and therapeutic rights for all genes discovered during the collaboration, returning a royalty on any product sales based on these genes to Galileo.

"The addition of Galileo's French-Canadian population data is highly complementary to Myriad's already extensive gene discovery technologies," said Dr. Mark Skolnick, Chief Scientific Officer of Myriad Genetics, Inc. "We anticipate that this collaboration with Galileo will lead to the acceleration of gene discoveries at Myriad."

"We are very excited to be working with Myriad Genetics, the world leader in discovery of important disease genes through comparative genetic analysis," said Dr. Philippe Douville, President of Galileo Genomics. "Our collaboration has the tremendous potential to speed the discovery of major disease genes, providing new opportunities to create novel drugs and diagnostic products in important therapeutic areas."

The anonymous French-Canadian genetic information will be used in conjunction with the vast assemblage of family resources available to Myriad through its Utah genealogy. The new information will provide an additional data set capable of accelerating Myriad's gene discovery programs. In addition to the discovery of important genes involved in breast cancer, brain cancer, melanoma and heart disease, Myriad has located two genes linked to human obesity, two genes associated with depression and five genes involved in heart disease. The precise location of these genes has been narrowed to small chromosomal regions and the Company expects the ensuing gene discovery process to greatly benefit from the new availability of DNA samples from the French-Canadian population.



GALILEO
G E N O M I C S
G É N O M I Q U E

880 McCaffrey
St. Laurent (Quebec) H4T 2C7
Tel : (514) 270-3991
Fax : (514) 270-5291
1-888-244-0388
www.galileogenomics.com